Cost-effectiveness of lipid-lowering therapy

Netherlands Heart Journal

Volumn 19, Issue 2, 2011, Pages 59-60

  Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RISK REDUCTION; TREATMENT DURATION;

EID: 79955457477     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0078-4     Document Type: Editorial

References (3)

1. van Nooten F, Davies GM, Jukema JW, Liem AH, Yap E, Hu XH. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J. 2011 (in press)
2. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
3. van Roeters Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr med Res Opin. 2008;24:685-694.